drugset / Trial / NCT05190575
TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer
NaSingle-groupOpen-labelTreatment
Summary
TST001 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. This is an open-label, single-arm phase II study to evaluate the efficacy and safety of TST001 for patients with CLDN18.2 positive previously treated unresectable advanced or metastatic Biliary Tract Cancer.
Timeline
- Start
- 2022-01-14
- Primary completion
- 2023-05-06
- Completion
- 2023-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Osemitamab | Monoclonal antibody | — | Intravenous |